ASH 2021

SEA-BCMA | Multiple Myeloma | Abstract #2740

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #1401

Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T-Cell Lymphoma With Less Than 10% CD30 Expression (SGN35-032, Trial in Progress)

Brentuximab Vedotin | Diffuse Large B-cell Lymphoma | Abstract #3564

Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2454

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1369

Brentuximab Vedotin in Combination With Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients With Early Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)

SEA-BCMA | Multiple Myeloma | Abstract #1197

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2467

Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1966

Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—A Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared by Age

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1390

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #2466

An Oncology Simulation Model to Estimate 10-year Progression-free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-cell Lymphoma: A United States Perspective

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2440

An Oncology Simulation Model to Estimate 10-year Progression-free Survival and Stem Cell Transplantation for Frontline Stage IIIor IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #135

The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma